The immune system holds the key to brain protection and repair

Brain key

Rewiring the Brain-Immune Network to Promote Neuroprotection and Fight Neurodegeneration

About ImmunoBrain Checkpoint

ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company developing novel neuroprotective immune therapies for neurodegenerative diseases. IBC licensed its platform IP from Yeda, the commercialization company of the Weizmann Institute of Science in Israel. IBC developed a proprietary fully human anti-PD-L1 antibody, engineered based on its mechanism of action to treat Alzheimer’s disease and dementia. IBC plans to start its first-in-human clinical trial in 2021.

Scientific Platform: Evidence-Based Dogma-Breaking Hypothesis

peripheral immune

The peripheral immune system plays a key role in maintaining the healthy brain, and helps mitigate neurological diseases

Immune dysfunction

Age-related Immune dysfunction is a major contributor to the onset and progression of neurodegenerative disorders

immune system

Boosting the immune system can restore the brain-immune network needed for neuroprotection and brain function

Read More >
Scientific Platform

Lead Program: IBC's Alzheimer's Disease Therapy

A novel, proprietary antibody targeting PD-L1 to treat Alzheimer's disease and dementia

immune system

Periodically blocks the PD-1/PD-L1 inhibitory immune pathway

Facilitates mobilizing

Facilitates mobilizing macrophages to the brain

Macrophages

Macrophages remove the neurotoxic form of misfolded proteins

brain restoration

Activates multiple processes of brain restoration

Rescues synapses

Rescues synapses and reduces inflammation

Restores brain function

Restores brain function

Immune dysfunction

Overcomes disease heterogeneity

High immunological safety

High immunological safety profile compared with clinically approved PD-L1 antibodies

Lead Program

Literature & Media

Molecular Psychiatry Cell biology
Nature Medicine
Nature Medicine
Play

Watch the Video

Brain key

Partnerships

Lonza
Alzheimer's Association
SBI-Holdings
Yeda
Tel-Aviv University
Cern
Israel Innovation Authority
Kymab

Team

Prof. Michal Schwartz
Co-founder and Chief Scientific Officer

●●

A world-renowned expert in Neuroimmunology who pioneered the field of nervous system repair, protection, and maintenance by the immune system. Schwartz is a professor of Neuroimmunology at the Weizmann Institute of Science (WIS).

She was the first to suggest, against the prevailing dogma at the time, that circulating immune cells are essential for supporting life-long functional brain plasticity in health and disease, and should be harnessed to help fighting brain pathologies.

These results led to the paradigm-shifting approach of developing an immunotherapy to combat neurodegenerative diseases. Her scientific publications have been extremely influential, as reflected by their high citation score. Schwartz has received numerous national and international awards, and served as president of the International Society of Neuroimmunology (2016-2018).

Prof. Michal Schwartz
Eti Yoles,Ph.D.

Eti Yoles, Ph.D.

Chief Operating Officer

Eti Yoles, Ph.D. Linkedin

Chief Operating Officer

●●

More than 20 years of high-level experience in managing biotechnology research and development, specifically in the field of neuro-immunology. Prior to joining ImmunoBrain Checkpoint, Eti served as CSO of Immunobrain Therapies, and prior to that, as managing director of NeuroQuest and as VP of Product R&D at Proneuron Biotechnologies. Dr. Yoles holds a B.Sc. in biology, M.Sc. in physiology, and Ph.D. in neurobiology from Bar Ilan University.

Jesse Cedarbaum, MD

Jesse M. Cedarbaum, MD

Acting Chief Medical Officer

Jesse M. Cedarbaum, MD Linkedin

Acting Chief Medical Officer

●●

Served as Vice President, Movement and Neuromuscular Disorders Clinical Development at Biogen Idec between 2014-2019. Prior to joining Biogen, Dr. Cedarbaum was Vice President, Global Clinical Development for Neuroscience at Bristol-Myers Squibb, where he was responsible for late-stage programs in neurology and psychiatry. He has also held senior clinical development positions at Cytokinetics, Elan and Regeneron.

Mr. Nathan Hevrony

Mr. Nathan Hevrony

Co-founder and Executive Chairman

Mr. Nathan Hevrony Linkedin

Co-founder and Executive Chairman

●●

Investor with a large portfolio of holdings with 35 years of experience in private equity and merchant banking, and 22 years of experience financing and developing life science technologies. Chairman of the Board and the controlling shareholder of Babcock Power. Board member and investor in various private companies. Philanthropist.

Carol David, Ph.D. VP

Carol David, Ph.D.

VP Manufacturing and Product Development

Carol David, Ph.D. Linkedin

VP Manufacturing and Product Development

●●

Over 20 years of pharmaceutical industry experience. She has worked for both diagnostic and biopharmaceutical companies, following products from early development through regulatory submission. Most recently, Carol was head of the Biosimilar CMC group at Teva Pharmaceuticals, leading a multi-functional team for development of several biosimilar products. Carol holds an M.Sc. and Ph.D. in Immunology from the WIS, and has post-doctoral experience at Yale University.

Kuti Baruch, Ph.D.

Kuti Baruch, Ph.D.

Head of Research and Development

Kuti Baruch, Ph.D. Linkedin

Head of Research and Development

●●

Over 10 years of biomedical research experience in the fields of neuroimmunology and therapeutic approaches to neurodegenerative conditions. During his Ph.D. studies at Prof. Schwartz’s laboratory, his research focused on brain-immune system crosstalk in neurodegenerative diseases, and targeting the peripheral immune system as a novel therapeutic approach for Alzheimer’s disease. Kuti holds a M.Sc. in Medical Science from Tel-Aviv University, and a Ph.D. in Neurobiology from the Weizmann Institute of Science.

Advisory Board

Paul Aisen, MD

Paul Aisen, MD

●●

Professor of Neurology; Director, Alzheimer’s Therapeutic Research Institute, University of Southern California.

Moses Chao, Ph.D

Moses Chao, Ph.D

●●

Professor, New York University School of Medicine. His laboratory defined the genes encoding the nerve growth factor receptor and his research interests are in defining mechanisms used by trophic factors to change synaptic plasticity.

Michael Davidson, MD

Michael Davidson, MD

●●

Professor of Psychiatry at the Sackler School of Medicine Tel Aviv and Mount Sinai School of Medicine NYC . Currently Executive President of the Alzheimer Center in Tel Aviv, an organization providing inpatient and community  care to several hundred demented elderly.

George Garibaldi, MD

George Garibaldi, MD

●●

Dr. Garibaldi has more than 25 years of global pharmaceutical and academic experience in early to late-stage drug development. Previously Vice President of Neuroscience and Product Development at Hoffmann-La Roche AG.

Lon Schneider, MD

Lon Schneider, MD

●●

Professor of Psychiatry and Behavioral Sciences. Director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer’s Disease Research Center (National Institutes of Health).

Philip Scheltens, MD

Philip Scheltens, MD

●●

Since 2000, Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam.

Dr. Jan Egebjerg, Ph.D

Dr. Jan Egebjerg, Ph.D

●●

SVP Grants and Prizes Lundbeckfoundation. Previously Senior Director of Neurodegeneration at Janssen since 2018. Previously he was Divisional Director for Neurodegeneration at H. Lundbeck A/S and ass. professor at Dept for Molecular Biology, University of Aarhus.

Board of Directors

Mr. David Ben-Ami

Mr. David Ben-Ami

●●

Over 25 years of experience in the health sector. His activities span from management to business development, corporate strategy, and entrepreneurship in the life sciences industry. Mr. Ben-Ami was the Founder and Executive Chairman of NASDAQ-listed company Macrocure Ltd. from 2008 to 2016.

Mr. Yaki Enoch

Mr. Yaki Enoch

●●

One of Israel’s most senior corporate executives, President of the Israeli Car Importers Association. Formerly a member of the Board of Directors of the Advisory Council to the Head of the Central Bank of Israel.

Mr. Jay Kranzler

Mr. Jay Kranzler

●●

Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years.

Pipeline

Pipeline table

News

12/10/2020

Another research group, Xing et al. publishes a paper substantiating IBC’s results and mechanism of action in the most recent Brain, Behavior, and Immunity.

Read More > Download file >

10/09/2020

Michal Schwartz, IBC’s Chief Scientific Officer, co-authored a paper in Cell Press Trends in Immunology looking into non-neuronal brain cells and the implications for #Alzheimersdisease therapy.

Read More >

26/08/2020

We are delighted to announce that we have been awarded a $1,000,000 grant from the Alzheimer's Association® under the 2020 Part the Cloud-Bill Gates Partnership Grant Program.

Read More > Download file >

17/08/2020

Earlier this year IBC's Chief Scientific Officer, Prof. Michal Schwartz, co-authored and published a review paper in the Journal of Immunology giving an overview of her 20 years of research.

Read More > Download file >

03/08/2020

Last week we attended the AAIC Virtual Conference 2020 and presented data on our innovative anti-PD-L1 antibody, IBC-Ab002.

Read More > Download file >

27/07/2020

Today marks the start of #AAIC20, the virtual Alzheimer’s Association International Conference. IBC’s Chief Scientific Officer, Prof. Michal Schwartz, will be presenting today at 11:30am CDT.

Read More > Download file >
Skip to content